Atlas Venture, Bain Capital, Forbion, and Sofinnova led a $245m Series A round in Aiolos Bio.

Atlas Venture, a venture capital firm, Bain Capital Life Sciences, a private investment firm, Forbion, a venture capital firm, and Sofinnova Investments, a venture capital firm in life sciences, led a $245m Series A round in Aiolos Bio, a clinical-stage biopharmaceutical company, with participation from RA Capital Management. "Aiolos has a unique opportunity to positively impact patients’ asthma outcomes. I’m excited for the opportunity to lead this innovative Company and the wealth of experience our talented team brings to bear, from operating large-scale clinical trials in asthma, to overseeing more than 30 FDA approvals, to leading successful product launches in immune conditions like asthma, rheumatoid arthritis, and IPF,” Khurem Farooq, Aiolos Bio Co-Founder and CEO.